Product Overview
[Drug Name]
Generic Name: Proglumide Tablets
Trade Name: Yabang Pharmaceutical
English Name: Proglumide Tablets
Chinese Pinyin: Binggu'an Pian
[Ingredients]
Proglumide. Chemical name: (±)-5-dipropylamino-4-benzamido-5-oxo-pentanoic acid.
[Properties]
This product is a white tablet.
[Indications]
Commonly used for gastric and duodenal ulcers, chronic superficial gastritis, and duodenitis.
[Dosage and Administration]
Oral. Adults: 0.4g each time, 3-4 times daily, 15 minutes before meals, for 30-60 days. Dosage schedule can also be determined based on gastroscopy or X-ray results.
Children: 10-15mg/kg each time, 3 times daily, 15 minutes before meals. The duration of treatment depends on the condition.
[Adverse Reactions]
This product has no significant side effects. Occasional adverse reactions include dry mouth, constipation, itching, insomnia, abdominal distension, and lower limb soreness, which generally do not require special treatment. Temporary leukopenia and mild transaminase elevations have been reported in some cases.
[Contraindications]
This product is contraindicated in patients with complete obstruction of the cystic duct or biliary tract.
[Precautions]
1. This product has a weaker inhibitory effect on gastric acid secretion than H2 receptor antagonists and is no longer used alone in clinical treatment of ulcers, but its choleretic effect is highly valued. 2. During treatment, tobacco, alcohol, irritating foods, and psychological trauma should be avoided.
[Use in Special Populations]
Precautions for Children: No studies have been conducted and no reliable references are available.
Precautions for Pregnant and Lactating Women: No studies have been conducted and no reliable references are available.
Precautions for Elderly People: No studies have been conducted and no reliable references are available.
[Drug Interactions]
This product does not affect the metabolism of other drugs. If used concomitantly with other anti-ulcer drugs, such as H2 receptor antagonists, it may enhance the inhibitory effect on gastric acid secretion and accelerate ulcer healing.
[Pharmacological Action]
This product is a gastrin receptor antagonist, with a chemical structure similar to the terminal chemical structures of two intestinal kinins: gastrin (G-17) and cholecystokinin (CCK). Its amide functional group specifically competes with gastrin for gastrin receptors on parietal cells, significantly inhibiting gastrin-induced gastric acid and pepsin secretion. It has no significant effect on gastric acid secretion induced by histamine or vagus nerve stimulation. It increases the content of hexosamine in the gastric mucosa, promotes glycoprotein synthesis, and has a protective and healing effect on the gastric mucosa. It can improve the symptoms of peptic ulcers and promote ulcer healing. This product does not cause rebound gastric acid secretion in the treatment of peptic ulcers and gastritis, and can maintain normal gastric acid secretion for up to six months after treatment discontinuation. In addition, this product has a choleretic effect through three pathways: ① By stimulating bile acid-independent bile secretion, it facilitates stone excretion and biliary tract flushing and dredging; ② By altering the stone-forming factors in bile, it significantly increases bicarbonate concentration and excretion volume, while reducing the concentrations of free bilirubin, cholesterol, and calcium ions; ③ By antagonizing CCK, it inhibits the endogenous CCK-stimulating effect, thereby expanding gallbladder capacity and diluting bile components within the gallbladder, thereby preventing stone formation. This product is safe, with an acute oral LD50 of 17.8g/kg in mice.
[Storage]
Keep in a dark, sealed container.
[Specifications]
0.2g
[Packaging]
0.2g*50s
[Expiry Life]
36 months
[Approval Number]
National Medicine Standard H32021429
[Manufacturer]
Jiangsu Yabang Epson Pharmaceutical Co., Ltd.
